Atherosclerosis-targeted liposome nanocarrier delivery system and preparation method therefor
US-2024424132-A1 · Dec 26, 2024 · US
Probenecid for use in treating epileptic diseases, disorders or conditions
US2020163916A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2020163916-A1 |
| Application number | US-201816630114-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jul 13, 2018 |
| Priority date | Jul 13, 2017 |
| Publication date | May 28, 2020 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in the subject. Preferably, the neurological disorder is an epileptic disease, disorder or condition.
First claim
Opening claim text (preview).
1 - 14 . (canceled) 15 . A method for treating a neurological disorder in a subject in need thereof, comprising administering to the subject probenecid or a pharmaceutical acceptable salt thereof, wherein the administration to the subject of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in said subject. 16 . The method according to claim 15 , wherein the neurological disorder is an epileptic disease, disorder or condition. 17 . The method according to claim 16 , wherein the epileptic disease, disorder or condition is selected from the group consisting of familial epilepsy, genetic epilepsy, structural/metabolic epilepsy and epilepsies with unknown cause. 18 . The method according to claim 16 , wherein the epileptic disease, disorder or condition is brain tumor-related epilepsy. 19 . The method according to claim 16 , wherein the epileptic disease, disorder or condition is a malformation of cortical development (MCD)-related epilepsy. 20 . The method according to claim 16 , wherein the epileptic disease, disorder or condition is a neurodegenerative-related epilepsy. 21 . The method according to claim 16 , wherein the epileptic disease, disorder or condition is a dysimmune epilepsy. 22 . The method according to claim 16 , wherein the subject is suffering from a treatment-resistant epileptic disease, disorder or condition. 23 . The method according to claim 15 , wherein said subject is a child. 24 . The method according to claim 15 , wherein said subject is an adult. 25 . The method according to claim 15 , wherein probenecid or the pharmaceutical acceptable salt thereof is administered to the subject at a dose ranging from 1 mg/kg/day to 100 mg/kg/day. 26 . The method according to claim 15 , wherein probenecid or the pharmaceutical acceptable salt thereof is administered orally or by injection. 27 . The method according to claim 15 , wherein probenecid or a pharmaceutical acceptable salt thereof is comprised within a pharmaceutical composition also comprising a pharmaceutically acceptable carrier or diluent. 28 . The method according to claim 15 , wherein probenecid or a pharmaceutical acceptable salt thereof is comprised within a medicament.
Assignees
Inventors
Classifications
- A61K31/195Primary
having an amino group · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
Antiepileptics; Anticonvulsants · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2020163916A1 cover?
- Probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in the subject. Preferably, the neurological disorder is an epileptic disease, disorder or condition.
- Who is the assignee on this patent?
- Paris Sciences Lettres Quartier Latin, Centre Nat Rech Scient, Inst Nat Sante Rech Med, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/195. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu May 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).